PERSONALIZED MEDICINE:FDA Approves First Next-Gen Sequencer as Diagnostic
Agency believes marketing authorization will speed up clinical use of genetic information.
The U.S. Food and Drug Administration granted the first marketing authorization for a next generation genomic sequencing platform, Illumina’s MiSeqDx, for use as a diagnostic. The approval marks a transition of next generation sequencing from research to clinical use as doctors will increasingly consider a patient’s genetic information in their diagnoses and treatment decisions. Read More